EI
TBPH icon

EAM Investors’s Theravance Biopharma TBPH Stock Holding History

EAM Investors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-66,296
Closed -$1.24M – 371
2025
Q4 		$1.24M Buy
66,296
+38
+0.1% +$630 0.14% 185
2025
Q3 		$967K Buy
+66,258
New +$837K 0.11% 200
2016
Q4 		– Sell
-114,204
Closed -$4.14M – 364
2016
Q3 		$4.14M Buy
114,204
+80,446
+238% +$2.24M 0.56% 24
2016
Q2 		$766K Buy
+33,758
New +$729K 0.12% 284

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's TBPH Position: Q1 2026 in Review

EAM Investors sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 66,296 shares — an estimated $1.24M sold.

EAM Investors first reported a position in TBPH in Q2 2016 and held it in 4 quarters. The position peaked at $4.14M in Q3 2016. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • EAM Investors reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 66,296 Theravance Biopharma shares in Q1 2026, an estimated $1.24M.
  • EAM Investors first reported a position in Theravance Biopharma in Q2 2016 and held it in 4 quarters.
  • EAM Investors's Theravance Biopharma position peaked at $4.14M in Q3 2016.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.